Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.30M | -58.24M | -62.80M | -65.53M | -70.96M |
| Total Depreciation and Amortization | 1.70M | 1.64M | 1.72M | 1.80M | 1.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.14M | 6.44M | 6.87M | 7.18M | 7.55M |
| Change in Net Operating Assets | 67.57M | 31.78M | 36.57M | 39.21M | 7.69M |
| Cash from Operations | 21.10M | -18.38M | -17.65M | -17.35M | -53.87M |
| Capital Expenditure | -58.00K | -36.00K | -30.00K | -21.00K | -316.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -58.00K | -36.00K | -30.00K | -21.00K | -316.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -28.00K | -3.38M | -5.07M | -7.31M | -8.42M |
| Issuance of Common Stock | 33.10M | 32.58M | 24.43M | 24.43M | 4.51M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 33.07M | 29.20M | 19.36M | 17.13M | -3.91M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.12M | 10.78M | 1.68M | -239.00K | -58.10M |